Boehringer Ingelheim: Privacy Has its Virtues
Executive Summary
Boehringer Ingelheim has beaten market growth for the past nine years and may continue to outperform rivals. Part of the secret: its private status affords the group a long-term outlook that's far trickier for its public peers to embrace.
You may also be interested in...
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin